Alector presents baselines characteristics for INFRONT-3 Phase 3 trial

Alector announced the presentation of a poster on participant baseline characteristics for the pivotal INFRONT-3 Phase 3 clinical trial evaluating the safety and efficacy of latozinemab in potentially slowing disease progression in individuals with frontotemporal dementia due to a progranulin gene mutation, FTD-GRN. The conference is being held in Amsterdam from September 19 – 22, 2024. Compared against available registry data, the baseline characteristics of symptomatic INFRONT-3 participants, including age, CDR plus NACC FTLD-SB score and NfL levels, were representative of the broader FTD-GRN registry population.